ROS Therapeutics ApS: Financial statements 2024
CVR: 39507501
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ROS Therapeutics ApS (CVR 39507501) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -583,751 and a net result of DKK -1,314,915 compared with DKK -1,152,395 the year before. Equity in the 2024 report amounted to DKK -6,575,721. The company had 1 employee in the financial year.
- Gross Profit
- DKK -583,751
- Profit/Loss
- DKK -1,314,915
- Equity
- DKK -6,575,721
- Total Assets
- DKK 1,335,109
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -584 t. | -1.3 mio. | -6.6 mio. | 1 |
| 2023 | - | -678 t. | -1.2 mio. | -5.3 mio. | 1 |
| 2022 | - | -3.1 mio. | -3.4 mio. | -4.1 mio. | 1 |
| 2021 | - | -4.8 mio. | -4.4 mio. | -758 t. | 1 |
| 2020 | - | -2 mio. | -1.9 mio. | 3.6 mio. | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ROS Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -677,648, and the net result was DKK -1,152,395.
About ROS Therapeutics ApS
ROS Therapeutics ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2018. The company is in liquidation. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Hanne Damgaard Jensen. The company is owned by Sandlykke A/S, HDJ & LEJ Invest ApS and ROS Therapeutics Holding ApS. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -543,530 and a net result of DKK -1,212,924 compared with DKK -1,314,915 the year before. Equity in the 2025 report amounted to DKK -7,954,408.